VIDEO: ‘Distinctive shift’ in gut microbiota after Rebyota treatment for C. difficile

CHICAGO — In a Healio video exclusive, Ken Blount, PhD, discusses successful restoration of gut microbiota and clonal engraftment as soon as 1 week after treatment with Rebyota in those with recurrent Clostridioides difficile infection.Blount and colleagues sought to quantify and define clonal engraftment and durable microbiome compositional changes with FDA-approved Rebyota (fecal microbiota, live-jslm/RBX2660, Ferring Pharmaceuticals) in the phase 3 PUNCH CD3 trial, which enrolled adult patients with at least one recurrent episode of C. difficile infection.Following standard of careRead More